Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials
Authors
Keywords
-
Journal
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-03-16
DOI
10.1007/s00432-021-03521-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- P-080Regorafenib combined with irinotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas: A randomized phase 2 trial (PRODIGE 58 – UCGI 35 – REGIRI)
- (2019) E Samalin et al. ANNALS OF ONCOLOGY
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
- (2019) Breelyn A Wilky et al. LANCET ONCOLOGY
- Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
- (2019) Nanna Bæk Møller et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Is there truly an increase in risk of cardiovascular and hematological adverse events with vascular endothelial growth factor receptor tyrosine kinase inhibitors?
- (2019) Luis Furuya-Kanamori et al. Expert Opinion On Drug Safety
- Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
- (2019) Kirsi M. Manz et al. ADVANCES IN THERAPY
- The discovery of the fundamental role of VEGF in the development of the vascular system
- (2019) Domenico Ribatti MECHANISMS OF DEVELOPMENT
- The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis
- (2018) Hampig Raphael Kourie et al. Future Oncology
- Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis
- (2018) Andrea Cipriani et al. LANCET
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular diseases in patients receiving small molecules with anti-vascular endothelial growth factor activity: A meta-analysis of approximately 29,000 cancer patients
- (2018) Matthias Totzeck et al. European Journal of Preventive Cardiology
- Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials
- (2018) Jing Li et al. CLINICAL DRUG INVESTIGATION
- Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial
- (2018) Joong-Won Park et al. JOURNAL OF HEPATOLOGY
- Sorafenib for Advanced and Refractory Desmoid Tumors
- (2018) Mrinal M. Gounder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
- (2017) Jiali Liu et al. BMJ-British Medical Journal
- Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis
- (2017) Jiali Liu et al. BMJ-British Medical Journal
- Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients
- (2016) Bo Liu et al. Oncotarget
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
- (2015) Pooja Ghatalia et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors
- (2014) P Ghatalia et al. BRITISH JOURNAL OF CANCER
- Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer
- (2013) G. N. Ton et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Venous thromboembolic events with vascular endothelial growth factor receptor tyrosine kinase inhibitors: A systematic review and meta-analysis of randomized clinical trials
- (2013) Guru Sonpavde et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Demystifying trial networks and network meta-analysis
- (2013) E. J. Mills et al. BMJ-British Medical Journal
- Risk of venous thromboembolic events associated with VEGFR-TKIs: A systematic review and meta-analysis
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
- (2010) Georgia Salanti et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Checking consistency in mixed treatment comparison meta-analysis
- (2010) S. Dias et al. STATISTICS IN MEDICINE
- Modeling between-trial variance structure in mixed treatment comparisons
- (2009) G. Lu et al. BIOSTATISTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started